Fluor's Guidance Cut Is the Old Story. The New One Is Worth Watching.

The market reacted to Fluor's Q2 earnings beat like a headline event. The stock jumped 17% on the day, pushing to $57, the highest level in 52 weeks. Adjusted EPS of $0.91 cleared the $0.71 consensus by 28%. Revenue of $4.33 billion beat the estimate by $365 million. All good.

Then the tape noticed that Fluor lowered its full-year adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization — a rough proxy for operating cash generation before capital spend) guidance from $525–$560 million to $500–$525 million. The guidance cut is the headline the market wanted. The story it tells is the wrong one.

The reduction reflects the removal of the Mexico joint venture contribution after Fluor completed its divestiture for $175 million. That was a legacy project, not a core operation. The midpoint dropped roughly $30 million because a piece of the portfolio left the company. That is portfolio cleanup, not demand deterioration.

The story the market is still pricing is the old Fluor: a fixed-price engineering and construction operator that got burned by cost overruns on large legacy projects, whose backlog was a mixed bag of profitable reimbursable work and toxic EPC (engineer, procure, construct) commitments that could turn negative overnight.

The numbers from this quarter tell a different story. Legacy project backlog is down to $119 million. Six months ago it was still in the hundreds of millions, dragging on margins and cash flow. At $119 million, it is effectively gone. The remaining $26.9 billion in total backlog is 85% reimbursable. In reimbursable contracts, the client pays actual costs plus a fee. The upside is capped, but the downside risk is too. That is the structural shift.

New awards in Q2 were $6.1 billion — up 245% from $1.8 billion a year earlier — and 89% of them were reimbursable. The Centrus nuclear fuel enrichment facility in the Mission Solutions segment, infrastructure work in Europe, a fertilizer project in Canada, gas compression on the U.S. west coast, and a phase-2 notice to proceed on LNG Canada. The pipeline is deep, and the risk profile of what's coming in is not what it was two years ago.

Segment margins tell the story more clearly than the headline EPS. Energy Solutions revenue fell 38% to $709 million, but segment profit jumped from $15 million to $88 million — a 12.4% margin versus 1.3% a year ago. That margin expansion came from favorable closeout items, including the former Mexico JV, so it's not purely repeatable. But the point is that the low-margin fixed-price work is exiting the revenue base.

Mission Solutions revenue was flat at $716 million while profit rose to $44 million, or 6.1% of revenue versus 4.6%. Backlog in that segment nearly doubled to $3.99 billion from $2.05 billion, driven by new DOE award-fee performance. That is where the government work pipeline — nuclear cleanup, national security infrastructure — translates into backlog with predictable fee structures.

Urban Solutions, the largest segment at $2.9 billion in revenue, saw profit grow from $29 million to $38 million on revenue up 40%. The margin stayed thin at 1.3%, weighed down by $44 million in cost growth on the substantially completed Gordie Howe International Bridge project. That project is done. It was a legacy pain point. Removing it from the quarterly comparison mechanically lifts Urban Solutions' margin trajectory in future quarters.

Here is what matters most over the next 12 months: with legacy fixed-price exposure effectively eliminated and the backlog overwhelmingly reimbursable, Fluor's adjusted EBITDA floor should be more stable than it has been in years. The $500–$525 million full-year target represents roughly $125–$131 million per quarter on a run-rate basis. If the post-Gordie Howe Urban Solutions segment can sustain even mid-single-digit margins and Energy and Mission hold their current trajectory, that target looks achievable without any miracle quarter.

The cash flow problem is the one real counterweight. Trailing twelve-month free cash flow is negative $330 million, and operating cash flow for the quarter was negative $317 million. A portion of that outflow — $357 million — was a one-time tax payment from the NuScale monetization, so the underlying operating cash flow is not as ugly as the headline. But the first six months of 2026 still saw $207 million in operating cash outflow. That's better than the $307 million outflow in the same period last year, but it's not cash generation yet.

What needs to happen is for the reimbursable work to start converting to positive operating cash flow. In reimbursable contracts, cash conversion tends to be cleaner than in fixed-price work because you're billing as you go. If the backlog mix is now 85% reimbursable, the cash flow trajectory should follow within a year or two, assuming no new legacy disasters.

On valuation, the stock trades at a forward P/E of roughly 1.8x on consensus full-year 2026 EPS estimates near $2.57–$2.59. That number looks absurdly cheap until you remember it's distorted by the NuScale gain and other non-recurring items that made 2025 a comparison anomaly. GAAP earnings in Q2 were $114 million ($0.81 per share), versus $2.46 billion a year ago that included $3.21 billion of equity-method earnings that won't repeat. The forward multiple doesn't carry much weight until the earnings base stabilizes.

Enterprise value is $5.8 billion against a $7.96 billion market cap — net debt is negative $1.97 billion. The company ended the quarter with $3.0 billion in cash and marketable securities, returned $300 million to shareholders in Q2 buybacks, and is targeting $1.4 billion in repurchases for the full year. Debt-to-equity sits at 38.5%. The balance sheet is solid, and the cash position gives management room to fund the buyback program even if operating cash flow stays weak through the transition.

The market's reaction function is caught between two things. The 17% pop on the earnings beat is the tape rewarding the EPS surprise. But the stock is already up 44% year-to-date, and the 120-day gain is 25%. Some of the business model improvement has clearly been bought. AInvest's aggregate signal still labels the stock Hold, which suggests the broader analyst base hasn't fully shifted its view despite the price move.

The setup over the next 12 months is this: legacy exposure is gone, reimbursable backlog is dominant, the EBITDA floor is cleaner, and the buyback program provides a valuation backstop if the stock stalls. The risk is execution — new reimbursable awards can still underperform if project management falters or if the macro environment makes clients cut spending. And operating cash flow hasn't proven positive yet on the new model.

If I were positioning here, I'd watch the operating cash flow trend more closely than the EPS headlines. The next two quarters should show whether the reimbursable-heavy backlog actually converts to cash. If H2 2026 sees operating cash flow turn positive and the $500–$525 million EBITDA target holds, the business has proven the transition works. At that point, the forward multiple rerates because the risk profile has changed structurally.

The tripwire is simpler to define. If adjusted EBITDA falls below $100 million in a full quarter outside of identifiable one-off items, or if new awards drop below $4 billion in a quarter while reimbursable share falls below 80%, the business model shift hasn't stuck. Cut and reassess. The whole thesis rests on the reimbursable portfolio holding its quality, not on volume alone.

This is not about chasing a stock that's already run 17% in a day. It's about a company that has systematically removed the projects that made it a speculative name and replaced them with work that has a cleaner margin profile. The guidance cut headline made the market think the old story is still alive. The backlog composition suggests otherwise.